Expertise in
17
conditions

Dr. Yallapragada S. Rao

Radiation Oncology
Inland Valley Hematology Oncology Associates
1910 Royalty Dr, 
Pomona, CA 
Expertise in
17
conditions
Inland Valley Hematology Oncology Associates
1910 Royalty Dr, 
Pomona, CA 

Overview

Yallapragada Rao is a Radiation Oncologist practicing medicine in Pomona, California.

Dr. Rao is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Prostate Cancer, Familial Prostate Cancer, and Primitive Neuroectodermal Tumor (PNET).

He is actively involved in clinical research, participating in 12 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Inland Valley Hematology Oncology Associates
1910 Royalty Dr, Pomona, CA 91767

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
32
conditions
Dr. Arya Amini
Radiation Oncology
Expertise in
32
conditions
Dr. Arya Amini
Radiation Oncology
Referral may be required

City Of Hope National Medical Center Radiology

1500 Duarte Rd, 
Duarte, CA 
 (13.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arya Amini is a Radiation Oncologist practicing medicine in Duarte, California. Dr. Amini is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Glossectomy, and Penectomy.

Expertise in
21
conditions
Dr. Mitchell R. Kamrava
Radiation Oncology
Expertise in
21
conditions
Dr. Mitchell R. Kamrava
Radiation Oncology
Referral may be required

Cedars-Sinai Radiation Oncology-Los Angeles

8720 Beverly Blvd, 
West Hollywood, CA 
 (36.4 miles away)
310-423-4208
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mitchell Kamrava is a Radiation Oncologist practicing medicine in West Hollywood, California. Dr. Kamrava is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Vaginal Cancer, Prostate Cancer, Prostatectomy, and Vitrectomy.

Expertise in
27
conditions
Dr. Percy P. Lee
Radiation Oncology
Expertise in
27
conditions
Dr. Percy P. Lee
Radiation Oncology
Referral may be required

Percy Lee, M.D.

Irvine, CA 
 (28.4 miles away)
847-342-6842
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Percy Lee is a Radiation Oncologist practicing medicine in Irvine, California. Dr. Lee is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Tissue Biopsy, and Liver Embolization.

Frequently Asked Questions about Dr. Yallapragada S. Rao

How do I make an appointment with Dr. Yallapragada S. Rao?

You can book an appointment with Dr. Yallapragada S. Rao by calling their office at 909-865-9517. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Yallapragada S. Rao a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Yallapragada S. Rao is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Yallapragada S. Rao specialize in?

While Dr. Yallapragada S. Rao is a Radiation Oncology, they have specific expertise in Breast Cancer, Prostate Cancer, and Familial Prostate Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Yallapragada S. Rao accept my insurance?

Dr. Yallapragada S. Rao accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 909-865-9517 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rao's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile